NOTTINGHAM, United Kingdom, 9 March 2018 – Xavant Technology (Pty) Ltd is attending the Physio First Conference in Nottingham, the United Kingdom, from 27 to 29 April 2018. The company, who is a leading developer of nerve stimulators for regional and general anesthesia, obtained clearance from the U.S Food and Drug Administration’s (FDA) in June 2017 to distribute their latest device, the Stimpod NMS460 in the United States. Their eyes are now set on the United Kingdom.
“We are excited to officially launch the Stimpod NMS460 to the UK market,” said Roche van Rensburg, Chairman of Xavant Technology (Pty) Ltd. “Our ground-breaking technology has the ability to help thousands of people in the U.K. as a valuable treatment asset for physiotherapists, neurologists, chiropractors, and medical pain practitioners.”
The Stimpod NMS460’s patented proprietary hybrid pulsed radio frequency (PRF) waveform lets practitioner facilitate the symptomatic relief and management of chronic intractable pain. It is also indicated as an adjunctive treatment in the management of post-surgical pain, post-traumatic acute pain problems, and an adjunct for pain control due to rehabilitation.
The Stimpod NMS460 has the potential to have a massive impact on the physiotherapy community as a non-invasive, non-drug solution with zero side effects and a fast onset of effect at a fraction of the cost of comparable treatments.
The device applies its patented PRF waveform to the affected area transcutaneously. This waveform creates electromagnetic effects similar to invasive pulsed radio frequency treatments, and several case studies have shown instant and dramatic relief of chronic intractable pain. The Stimpod NMS460 also incorporates the nerve-locating technology which features a nerve mapping probe that enables practitioners to locate nerves and evaluate the treatment progress of damaged nerves.